Second-Line Capecitabine and Oxaliplatin Combination for Gemcitabine-Resistant Advanced Pancreatic Cancer

Evaluation of Prognostic Factors and Survival Results in Pancreatic Carcinomas in Turkey

(2014) Emine Canyilmaz et al.   Asian Pacific Journal of Cancer Prevention

Pancreatic Cancer Incidence and Mortality Patterns in China, 2009

(2014) Wan-Qing Chen et al.   Asian Pacific Journal of Cancer Prevention

Incidence and Trends of Malignant and Benign Pancreatic Lesions in Yazd, Iran between 2001 and 2011

(2013) Shokouh Taghipour Zahir et al.   Asian Pacific Journal of Cancer Prevention

Racial and Social Economic Factors Impact on the Cause Specific Survival of Pancreatic Cancer: A SEER Survey

(2013) Rex Cheung   Asian Pacific Journal of Cancer Prevention

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Long Term Survivors with Metastatic Pancreatic Cancer Treated with Gemcitabine Alone or Plus Cisplatin: a Retrospective Analysis of an Anatolian Society of Medical Oncology Multicenter Study

(2012) Ali Inal et al.   Asian Pacific Journal of Cancer Prevention

A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic Cancer

(2012) Jong Gwon Choi et al.   Cancer Research and Treatment

Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group

(2011) Uwe Pelzer et al.   EUROPEAN JOURNAL OF CANCER

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer

(2008) Henry Q. Xiong et al.   CANCER

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER